# Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility

> **NCT00617370** · NA · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 38 (actual)

## Conditions studied

- Breast Cancer
- Adenocarcinoma of the Breast

## Interventions

- **DRUG:** epirubicin, cyclophosphamide, Paclitaxel,

## Key facts

- **NCT ID:** NCT00617370
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2005-07
- **Final completion:** 2008-06
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2015-12-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00617370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00617370, "Dose-Dense Epirubicin and Cyclophosphamide (EC) Followed by Paclitaxel in Breast Cancer: Feasibility". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00617370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*